The market for cervical dysplasia is expected to grow at a CAGR of around 6.9% from 2020 to 2027 and expected to reach the market value of around US$ 852.4 Mn by 2027.
Cervical Dysplasia or cervical intraepithelial neoplasia (CIN) is a precancerous condition where abnormal cell growth occurs on the surface lining of the cervix or endocervical canal, the opening between the uterus and the vagina. The condition is most common in women under age 30 but can develop at any age. It usually causes no symptoms and is most often discovered by a routine Pap test. Mild cervical dysplasia can be resolved without treatment and may only require careful observation with Pap tests every three or six months, whereas moderate-to-severe cervical dysplasia usually requires treatment to remove the abnormal cells and reduce the risk of cervical cancer. Human papillomavirus (HPV) is the primary cause of cervical dysplasia, which is an infection common in women and men. A healthy immune system can eliminate HPV and clears the infection but in some women, the infection persists and leads to cervical dysplasia. There are more than 200 different HPV viruses and around half of them are sexually transmitted. Moreover, the most common types that are strongly associated with cervical cancer are HPV 16 and HPV 18.
Market Dynamics
The growing female population that comes under the reproductive age group, raising awareness about the condition, and availability of advanced medical facilities, increasing cases of STDs, increasing vaginal infection, increasing smoking propensity, drug abuse, are some of the major factors driving the market growth. The rising prevalence of cancer coupled with the increasing number of awareness campaigns for the early diagnosis of the disease is supporting the market growth. Additionally, a report published by the WHO stated that this disease is the most common cause of HPV-associated cancer in women.
On the other hand, lack of medical facilities in the developing economies, high cost associated with the surgery, expensive drug cost, the absence of the reimbursement policies, and lack of skilled physicians are some of the factors anticipated to limit the growth to an extent throughout the forecast timeframe from 2020 to 2027.
Segment Instance
Hospitals is the leading segment by end users in the cervical dysplasia market
The hospital segment has registered a maximum revenue share (%) in 2019. The segment is also projected to maintain its dominance over the forecast period from 2020 to 2027. The presence of efficient products and professionals who can effectively use these test equipment for the treatment is supporting the segmental market value. The increasing investment in the hospitals for the development of technologically advanced infrastructure for the treatment of patients is boosting the market growth.
North America accounted for the maximum revenue share (%) in the Cervical Dysplasia market
In 2019, North America is leading the market with maximum revenue share (%) in the global market. The well-established healthcare infrastructure and emerging economies of the region are accelerating the regional market value. The presence of major players in the region is further bolstering the regional market value. Additionally, the ongoing research and development activities by the major players of the region are supporting the regional market growth.
Key Market Players
The players profiled in the report include Abbott Laboratories (US), Becton, Dickinson, and Company (US), F. Hoffmann La-Roche Ltd. (Switzerland), GlaxoSmithKline Plc. (UK), Hologic, Inc. (US), OncoHealth Corporation, Qiagen N.V. (Germany), Quest Diagnostics, Inc. (US), and others. The major market players were involved in mergers and acquisitions, partnerships & collaborations, and new product development for the expansion of market share (%).
Market Segmentation
Market By Treatment Type
Surgery
Chemotherapy
Therapeutic HPV Vaccines
Radiation Therapy
Other Treatment Types
Market By End Users
Hospitals
Diagnostic Centers
Ambulatory Surgery Centers
Specialty Clinics
Research & Academic Institutes
Market By Geography
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Cervical Dysplasia
1.1. Definition and Scope
1.1.1. Definition of Cervical Dysplasia
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Cervical Dysplasia Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Cervical Dysplasia Market By Molecule Type
1.2.3. Cervical Dysplasia Market By End Users
1.2.4. Cervical Dysplasia Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Cervical Dysplasia Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Cervical Dysplasia Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2019
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Cervical Dysplasia Market By Molecule Type
4.1. Introduction
4.2. Cervical Dysplasia Revenue By Molecule Type
4.2.1. Cervical Dysplasia Revenue (US$ Mn) and Forecast, By Molecule Type, 2016-2027
4.2.2. Surgery
4.2.2.1. Surgery Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.3. Chemotherapy
4.2.3.1. Chemotherapy Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.4. Therapeutic HPV Vaccines
4.2.4.1. Therapeutic HPV Vaccines Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.5. Radiation Therapy
4.2.5.1. Radiation Therapy Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.6. Other Treatment Types
4.2.6.1. Other Treatment Types Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 5. Cervical Dysplasia Market Revenue By End Users
5.1. Introduction
5.2. Cervical Dysplasia Revenue (US$ Mn) By End Users
5.2.1. Cervical Dysplasia Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
5.2.2. Hospitals
5.2.2.1. Hospitals Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Diagnostic Centers
5.2.3.1. Diagnostic Centers Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Ambulatory Surgery Centers
5.2.4.1. Ambulatory Surgery Centers Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Specialty Clinics
5.2.5.1. Specialty Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.6. Research & Academic Institutes
5.2.6.1. Research & Academic Institutes Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. North America Cervical Dysplasia Market By Country
6.1. North America Cervical Dysplasia Overview
6.2. U.S.
6.2.1. U.S. Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
6.2.2. U.S. Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
6.3. Canada
6.3.1. Canada Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
6.3.2. Canada Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
6.4. North America PEST Analysis
CHAPTER 7. Europe Cervical Dysplasia Market By Country
7.1. Europe Cervical Dysplasia Market Overview
7.2. U.K.
7.2.1. U.K. Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
7.2.2. U.K. Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
7.3. Germany
7.3.1. Germany Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
7.3.2. Germany Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
7.4. France
7.4.1. France Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
7.4.2. France Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
7.5. Spain
7.5.1. Spain Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
7.5.2. Spain Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
7.6. Rest of Europe
7.6.1. Rest of Europe Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016-2027
7.6.2. Rest of Europe Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016-2027
7.7. Europe PEST Analysis
CHAPTER 8. Asia Pacific Cervical Dysplasia Market By Country
8.1. Asia Pacific Cervical Dysplasia Market Overview
8.2. China
8.2.1. China Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
8.2.2. China Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
8.3. Japan
8.3.1. Japan Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
8.3.2. Japan Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
8.4. India
8.4.1. India Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
8.4.2. India Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
8.5. Australia
8.5.1. Australia Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
8.5.2. Australia Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
8.6. South Korea
8.6.1. South Korea Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
8.6.2. South Korea Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
8.7.2. Rest of Asia-Pacific Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Cervical Dysplasia Market By Country
9.1. Latin America Cervical Dysplasia Market Overview
9.2. Brazil
9.2.1. Brazil Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
9.2.2. Brazil Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
9.3. Mexico
9.3.1. Mexico Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
9.3.2. Mexico Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
9.4. Rest of Latin America
9.4.1. Rest of Latin America Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
CHAPTER 10. Middle East & Africa Cervical Dysplasia Market By Country
10.1. Middle East & Africa Cervical Dysplasia Market Overview
10.2. Saudi Arabia
10.2.1. Saudi Arabia Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
10.2.2. Saudi Arabia Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
10.3. UAE
10.3.1. UAE Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
10.3.2. UAE Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By Molecule Type, 2016 - 2027
10.4.2. Rest of Middle East & Africa Cervical Dysplasia Market Revenue (US$ Mn) and Forecast By End Users, 2016 - 2027
CHAPTER 11. PLAYER ANALYSIS OF CERVICAL DYSPLASIA MARKET
11.1. Cervical Dysplasia Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Cervical Dysplasia Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. COMPANY PROFILE
12.1. Abbott Laboratories (US)
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (US$ Mn), 2019
12.1.3.2. Abbott Laboratories (US) 2019 Cervical Dysplasia Business Regional Distribution
12.1.4. Product/ Service and Specification
12.1.5. Recent Developments & Business Strategy
12.1.6. Manufacturing Plant Footprint Analysis
12.2. Becton, Dickinson and Company (US)
12.3. F. Hoffmann La-Roche Ltd. (Switzerland)
12.4. GlaxoSmithKline Plc. (UK)
12.5. Hologic, Inc. (US)
12.6. OncoHealth Corporation
12.7. Qiagen N.V. (Germany)
12.8. Quest Diagnostics, Inc. (US)
12.9. Others